These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1730895)

  • 1. Inefficient bacteriolysis of Escherichia coli by serum from human neonates.
    Lassiter HA; Tanner JE; Miller RD
    J Infect Dis; 1992 Feb; 165(2):290-8. PubMed ID: 1730895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement factor 9 deficiency in serum of human neonates.
    Lassiter HA; Watson SW; Seifring ML; Tanner JE
    J Infect Dis; 1992 Jul; 166(1):53-7. PubMed ID: 1607708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. K-1 antigen of Escherichia coli: epidemiology and serum sensitivity of pathogenic strains.
    Pitt J
    Infect Immun; 1978 Oct; 22(1):219-24. PubMed ID: 103825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Supplemental complement component C9 enhances the capacity of neonatal serum to kill multiple isolates of pathogenic Escherichia coli.
    Lassiter HA; Wilson JL; Feldhoff RC; Hoffpauir JM; Klueber KM
    Pediatr Res; 1994 Apr; 35(4 Pt 1):389-96. PubMed ID: 8047374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutrophil-mediated killing, opsonization, and serum-mediated killing of Escherichia coli K1 by neonatal rats.
    Lassiter HA; Christensen RD; Parker C; Rothstein G
    Biol Neonate; 1988; 53(3):156-62. PubMed ID: 3285898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic regulation of E. coli K1 by serum from neonatal rats is enhanced following intraperitoneal administration of human IgG.
    Lassiter HA; Christensen RD; Parker CJ
    J Infect Dis; 1989 Mar; 159(3):518-25. PubMed ID: 2644382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bactericidal, bacteriolytic and opsonic activity of human serum against Escherichia coli.
    Rozenberg-Arska M; Porsius JC; Jaarsma EY; Verhoef J
    J Med Microbiol; 1986 Sep; 22(2):143-9. PubMed ID: 3528498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The interaction of Escherichia coli with normal human serum: the kinetics of serum-mediated lipopolysaccharide release and its dissociation from bacterial killing.
    Tesh VL; Duncan RL; Morrison DC
    J Immunol; 1986 Aug; 137(4):1329-35. PubMed ID: 3525676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human serum complement requirements for bacterial killing and protoplast lysis of Escherichia coli ML308 225.
    Allen RJ; Scott GK
    J Gen Microbiol; 1981 Mar; 123(1):179-81. PubMed ID: 7033454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of purified lipopolysaccharide on the bactericidal reaction of human serum complement.
    Allen RJ; Scott GK
    J Gen Microbiol; 1980 Mar; 117(1):65-72. PubMed ID: 6993628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition.
    Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
    J Immunol; 1983 Nov; 131(5):2563-9. PubMed ID: 6355296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escherichia coli in bacteremia: K and O antigens and serum sensitivity of strains from adults and neonates.
    McCabe WR; Kaijser B; Olling S; Uwaydah M; Hanson LA
    J Infect Dis; 1978 Jul; 138(1):33-41. PubMed ID: 355575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Murine hybridoma antibodies enhance bactericidal activity of human cord blood against K1 Escherichia coli strains.
    Kim KS; Cross AS; Kaufmann B; Zollinger W; Sadoff J
    Pediatr Res; 1990 Dec; 28(6):667-70. PubMed ID: 1704500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement component C9 enhances the capacity of beta-lactam antibiotics to kill Escherichia coli in vitro and in vivo.
    Jung E; Feldhoff RC; Walz BM; Drehs MM; Buchheit JQ; Lassiter HA
    Am J Med Sci; 1998 May; 315(5):307-13. PubMed ID: 9587087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of Serratia marcescens to human serum: antagonism of serum bactericidal activity by IgG immunoglobulins of homologous rabbit anti-O sera.
    Traub WH
    Zentralbl Bakteriol A; 1980 Feb; 246(1):26-49. PubMed ID: 6158811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of lipopolysaccharide and capsule in the serum resistance of bacteremic strains of Escherichia coli.
    Cross AS; Kim KS; Wright DC; Sadoff JC; Gemski P
    J Infect Dis; 1986 Sep; 154(3):497-503. PubMed ID: 3525697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The bactericidal activity of sera of healthy neonates and newborns with hyperbilirubinaemia to E. coli.
    Miler I; Vondrácek J; Hromádková L
    Czech Med; 1979; 2(1-2):29-40. PubMed ID: 393477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monobactam antibiotics in subinhibitory concentrations enhance opsonophagocytosis and serum bacteriolysis in certain Escherichia coli strains.
    Veringa E; Box A; Rozenberg-Arska M; Verhoef J
    Drugs Exp Clin Res; 1988; 14(1):1-8. PubMed ID: 3292179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
    Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
    J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further characterization of "promptly" and "delayed" human serum-sensitive strains of Serratia marcescens.
    Traub WH; Fukushima PI
    Zentralbl Bakteriol Orig A; 1979 Dec; 245(4):495-511. PubMed ID: 44945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.